Table 2: Matching characteristics of medicare patients with NVAF with and without stroke and bleeding events.

Major bleeding events
Matching characteristics Ischemic strokeICHOther major bleeds
Event N = 7,799Control N = 33,084Event N = 1,276Control N = 5,097Event N = 14,996Control N = 60,058

Age at AF diagnosis, years
 Mean (SD)81.1 (7.6)81.1 (7.9)79.9 (7.3)79.9 (7.6)80.0 (7.7)79.8 (7.8)
Age, categorized, n (%)
 65–69 years626 (8.0%)2,676 (8.1%)119 (9.3%)482 (9.5%)1,498 (10.0%)6,282 (10.5%)
 70–74 years1,058 (13.6%)4,569 (13.8%)197 (15.4%)815 (16.0%)2,408 (16.1%)9,916 (16.5%)
 75–79 years1,582 (20.3%)6,647 (20.1%)285 (22.3%)1,156 (22.7%)3,328 (22.2%)13,537 (22.5%)
 80–84 years1,791 (23.0%)7,318 (22.1%)319 (25.0%)1,235 (24.2%)3,295 (22.0%)12,696 (21.1%)
 ≥85 years2,742 (35.2%)11,874 (35.9%)356 (27.9%)1,409 (27.6%)4,467 (29.8%)17,621 (29.3%)
Gender, n (%)
 Male2,913 (37.4%)12,287 (37.1%)634 (49.7%)2,506 (49.2%)6,507 (43.4%)25,669 (42.7%)
 Female4,886 (62.7%)20,797 (62.9%)642 (50.3%)2,591 (50.8%)8,489 (56.6%)34,389 (57.3%)
Race, n (%)
 White7,194 (92.2%)31,539 (95.3%)1,191 (93.3%)4,901 (96.2%)14,018 (93.5%)57,668 (96.0%)
 Black445 (5.7%)1,012 (3.1%)50 (3.9%)120 (2.4%)678 (4.5%)1,628 (2.7%)
 Hispanic66 (0.9%)202 (0.6%)17 (1.3%)29 (0.6%)126 (0.8%)306 (0.5%)
 Other85 (1.1%)288 (0.9%)16 (1.3%)44 (0.9%)156 (1.0%)408 (0.7%)
 Unknown9 (0.1%)43 (0.1%)2 (0.2%)3 (0.1%)18 (0.1%)48 (0.1%)
US geographic location, n (%)
 Northeast1,547 (19.8%)6,408 (19.4%)251 (19.7%)975 (19.1%)3,251 (21.7%)12,450 (20.7%)
 South1,970 (25.3%)8,599 (26.0%)317 (24.8%)1,270 (24.9%)4,151 (27.7%)16,768 (27.9%)
 Midwest3,227 (41.4%)14,034 (42.4%)525 (41.1%)2,160 (42.4%)5,818 (38.8%)24,257 (40.4%)
 West1,051 (13.5%)4,043 (12.2%)183 (14.3%)692 (13.6%)1,767 (11.8%)6,570 (10.9%)
 Other/unknown4 (0.1%)3 (0.0%)0 (0.0%)0 (0.0%)9 (0.1%)12 (0.0%)
Year of AF diagnosis, n (%)
 2000–20034,919 (63.1%)20,082 (60.7%)715 (56.0%)2,651 (52.0%)8,935 (59.6%)33,254 (55.4%)
 2004–20062,132 (27.3%)9,449 (28.6%)403 (31.6%)1,700 (33.4%)4,359 (29.1%)18,786 (31.3%)
 2007–2009748 (9.6%)3,553 (10.7%)158 (12.4%)746 (14.6%)1,704 (11.4%)8,018 (13.4%)
Duration of study enrollment, n (%)
 3–<6 months1,571 (20.1%)6,604 (20.0%)342 (26.8%)1,324 (26.0%)2,123 (14.2%)8,582 (14.3%)
 6–<12 months1,341 (17.2%)5,671 (17.1%)202 (15.8%)839 (16.5%)2,455 (16.4%)9,838 (16.4%)
 12–<18 months933 (12.0%)4,030 (12.2%)138 (10.8%)570 (11.2%)1,812 (12.1%)7,345 (12.2%)
 18–<24 months740 (9.5%)3,160 (9.6%)114 (8.9%)468 (9.2%)1,576 (10.5%)6,354 (10.6%)
 24–36 months3,214 (41.2%)13,621 (41.2%)480 (37.6%)1,896 (37.2%)7,030 (46.9%)27,939 (46.5%)
Warfarin use, n (%)
 Yes2,568 (32.9%)10,087 (30.5%)532 (41.7%)1,968 (38.6%)5,594 (37.3%)20,576 (34.3%)
 No5,231 (67.1%)22,997 (69.5%)744 (58.3%)3,129 (61.4%)9,402 (62.7%)39,482 (65.7%)

ICH: intracranial hemorrhage; SD: standard deviation.